Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Ono Pharmaceutical Co., Ltd.
University of California, San Francisco
Emory University
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Nationwide Children's Hospital
Taipei Medical University
Australian & New Zealand Children's Haematology/Oncology Group
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Ann & Robert H Lurie Children's Hospital of Chicago
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Burzynski Research Institute
Dana-Farber Cancer Institute
Pediatric Brain Tumor Consortium